Inmunoterapia: Nuevo paradigma en el tratamiento del cáncer de pulmón microcítico

51 / 62

Best change from baseline
in target lesion size, %
100
80
60
40
20
–20
–40
–60
–80
–100
Non-response
Response
0
Confirmed ORR was 9.5% (95%CI 1.2, 30.4) with PR in 2 patients
Median PFS was 1.9 months (95%CI 1.8, 4.3)
Median OS was 6.0 months (95%CI 1.9, 12.0)